Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40

Eduardo M. Sotomayor, Ivan Borrello, Erev Tubb, Frédérique Marie Rattis, Harold Bien, Zhengbin Lu, Steve Fein, Stephen Schoenberger, Hyam I. Levitsky

Research output: Contribution to journalArticle

Abstract

Tumor antigen-specific T-cell tolerance limits the efficacy of therapeutic cancer vaccines. Antigen-presenting cells mediate the induction of T-cell tolerance to self-antigens. We therefore assessed the fate of tumor-specific CD4+ T cells in tumor-bearing recipients after in vivo activation of antigen-presenting cells with antibodies against CD40. Such treatment not only preserved the responsiveness of this population, but resulted in their endogenous activation. Established tumors regressed in vaccinated mice treated with antibody against CD40 at a time when no response was achieved with vaccination alone. These results indicate that modulation of antigen-presenting cells may be a useful strategy for enhancing responsiveness to immunization.

Original languageEnglish (US)
Pages (from-to)780-787
Number of pages8
JournalNature medicine
Volume5
Issue number7
DOIs
StatePublished - Jul 1 1999

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Conversion of tumor-specific CD4<sup>+</sup> T-cell tolerance to T-cell priming through in vivo ligation of cd40'. Together they form a unique fingerprint.

  • Cite this

    Sotomayor, E. M., Borrello, I., Tubb, E., Rattis, F. M., Bien, H., Lu, Z., Fein, S., Schoenberger, S., & Levitsky, H. I. (1999). Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40. Nature medicine, 5(7), 780-787. https://doi.org/10.1038/10503